| The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy S Kandel, P Adhikary, G Li, K Cheng Cancer letters 510, 67-78, 2021 | 88 | 2021 |
| Discovery of Small Anti‐ACE2 Peptides to Inhibit SARS‐CoV‐2 Infectivity P Adhikary, S Kandel, UF Mamani, B Mustafa, S Hao, J Qiu, J Fetse, Y Liu, ... Advanced Therapeutics, 2100087, 2021 | 21 | 2021 |
| Recent advances in the development of therapeutic peptides J Fetse, S Kandel, UF Mamani, K Cheng Trends in Pharmacological Sciences 44 (7), 425-441, 2023 | 11 | 2023 |
| Study of prevalence of Candida albicans among the patients attending to out-patient services of Gynaecology and Obstetrics Department with complaint of vaginal discharge S Kandel, R Shrestha, P Adhikary World Journal of Pharmacy and Pharmaceutical Sciences 6, 1457-1463, 2017 | 2 | 2017 |
| Discovery of Anti‐CD47 Peptides as Innate Immune Checkpoint Inhibitors B Mustafa, J Fetse, S Kandel, CY Lin, P Adhikary, UF Mamani, Y Liu, ... Advanced Therapeutics 6 (12), 2300114, 2023 | | 2023 |
| Discovery of Anti-CD47 Peptides as Innate Immune Checkpoint Inhibitors KC Bahaa Mustafa, John Fetse, Sashi Kandel, Chien-Yu Lin, Pratik Adhikary ... Advanced Therapeutics, 2023 | | 2023 |
Pratik AdhikaryFormulation Scientist在 mail.umkc.edu 的电子邮件经过验证
Pratik AdhikaryFormulation Scientist在 mail.umkc.edu 的电子邮件经过验证